Belsomra (Suvorexant) Cost in Pennsylvania: 2026 Pricing, Insurance, and Savings Guide

Suvorexant, marketed under the brand name Belsomra, is an FDA-approved oral medication that blocks orexin receptors (a dual orexin receptor antagonist or DORA) to treat insomnia with sleep initiation or maintenance difficulties. The medication comes in tablet form at 5 mg, 10 mg, 15 mg, and 20 mg strengths and carries Schedule IV controlled substance status. Suvorexant differs from lemborexant (Dayvigo), another DORA medication, and from traditional sedative-hypnotics such as zolpidem (Ambien) and eszopiclone (Lunesta), which instead target GABA-A receptors.

The direct answer: what you pay for Belsomra in Pennsylvania depends on whether you have commercial insurance, Medicaid, or no coverage, on which pharmacy you use, and on whether a manufacturer or third-party discount applies at the counter, and these variables shift often enough that any single "average price" quoted for the state should be treated as a starting estimate, not a number to plan a budget around. As of May 2026, there is no FDA-approved generic suvorexant on the market, which the FDA Orange Book can be used to confirm at any time, so cash-pay relief from generic competition is not currently available and any generic-price claim you see elsewhere should be verified against the current Orange Book listing before you rely on it.

Why there is no single "Belsomra price" for Pennsylvania

Manufacturer list price, pharmacy cash price, and what an insured patient actually pays are three different numbers. Merck has publicly listed Belsomra at a price in the range of several hundred dollars for a 30-tablet supply in recent years, but list price is rarely what anyone pays. Retail cash prices vary by pharmacy and change over time as pharmacy benefit manager contracts and discount-card rates shift. Because this article cannot verify a current, pharmacy-specific cash price for Pennsylvania as of a fixed date, we are not stating a single average figure here. If a source quotes you a precise statewide average (for example, "$85 a month"), treat that as unverified until you confirm it with a pharmacy directly, since prices differ by county, chain, and month.

What is established without needing verification: there is no FDA-approved generic suvorexant, so no patient in Pennsylvania can currently obtain a generic-tier price for the FDA-approved product. That fact is confirmed by the Orange Book link above and is unlikely to change without an FDA announcement.

Does Pennsylvania Medicaid cover Belsomra?

Pennsylvania Medical Assistance (Medicaid) programs, like most state Medicaid programs, generally require prior authorization for brand-name insomnia drugs that lack a generic equivalent, and typically expect documentation of a diagnosed insomnia disorder and often a prior trial of a lower-cost first-line agent. The specific criteria, the managed care organization's exact turnaround time for a decision, and any dollar copay are set by the Pennsylvania Department of Human Services and by each Medicaid managed care organization (for example, AmeriHealth Caritas, UPMC Health Plan, or Highmark Wholecare), and these details are revised periodically. This article cannot confirm the current version of those criteria, so anyone relying on Medicaid coverage should pull the current formulary and prior authorization policy directly from their MCO or from the PA Department of Human Services rather than assuming a fixed process or fixed turnaround window.

Clinical guidelines matter here because insurers often use them to justify prior authorization criteria. Guidance from sleep medicine specialty bodies has recommended cognitive behavioral therapy for insomnia (CBT-I) as a first-line approach for chronic insomnia, with medication as an adjunct or second-line option. If your plan requires you to document a CBT-I attempt or a failed trial of a generic sedative-hypnotic before approving Belsomra, that requirement is consistent with this broader guideline pattern, though the exact wording of Pennsylvania's Medicaid policy needs to be checked directly rather than assumed from national guidelines.

For patients enrolled in both Medicare and Medicaid, Medicare Part D is the primary payer for outpatient prescriptions, and Belsomra commonly sits on non-preferred brand tiers on Part D formularies. Tier placement and the resulting copay differ by plan and are published annually in each plan's formulary; check the specific Part D plan's current formulary rather than relying on a general estimate.

Commercial insurance in Pennsylvania: what is likely true, and what needs a phone call

Pennsylvania's major commercial carriers, including Highmark Blue Cross Blue Shield, UPMC Health Plan, Independence Blue Cross, Aetna, and Cigna, generally place brand-name sleep medications like Belsomra on a preferred- or non-preferred-brand tier and commonly apply prior authorization, sometimes paired with step therapy through a generic sedative-hypnotic first. That structure is standard industry practice for a branded drug without a generic alternative. What this article will not do is publish specific dollar copay ranges by carrier, because those figures change with each plan year and differ by employer group, and an outdated or wrong number is worse than no number. The reliable way to find your actual cost is to call the member services number on your insurance card or check your plan's online formulary tool before filling the prescription, and to ask specifically whether prior authorization or step therapy applies to Belsomra under your plan.

The Merck savings card and other discount options

Merck typically provides a discount card designed to lower out-of-pocket expenses for patients with commercial insurance, though it generally does not cover those with Medicare, Medicaid, Tricare, or similar government insurance plans. These savings programs usually need to be activated prior to filling a prescription and limit the discount amount per prescription and annually. Merck generally maintains a patient assistance program for uninsured and underinsured individuals who meet income criteria relative to federal poverty guidelines. Since program terms, eligibility rules, and availability vary annually, check Merck's current patient support information or contact your doctor's office to verify which programs apply now rather than relying on previous year details.

Third-party discount cards such as GoodRx, RxSaver, and SingleCare are free to use, require no insurance, and can sometimes beat an insured copay, particularly for patients on high-deductible plans early in the plan year. These discounts do not count toward an insurance deductible. Actual discounted prices at Pennsylvania pharmacies are not something this article can verify at a fixed number, since they change frequently and vary by zip code; check the app or website directly before assuming a specific price.

A statement attributed to a named physician appeared in the prior version of this page without a verifiable source and has been removed. If a genuine, attributable quotation from a Pennsylvania sleep medicine specialist becomes available, it can be added with proper sourcing during medical review.

Compounded suvorexant in Pennsylvania

Licensed 503A compounding pharmacies in Pennsylvania can prepare suvorexant for an individual patient under a valid prescription, which is permitted under federal law (the Drug Quality and Security Act) and under Pennsylvania State Board of Pharmacy regulations, including non-sterile compounding standards. This option is typically considered when a patient needs a formulation that is not commercially available, such as a liquid rather than a tablet.

Compounded suvorexant is not an FDA-approved product. FDA guidance generally indicates that compounded drugs have not been evaluated by the FDA for safety, effectiveness, or quality in the way an approved drug has, and are intended for situations where an FDA-approved product does not meet a specific patient's medical need, not as a routine low-cost substitute. Compounded suvorexant has not undergone the bioequivalence testing that generic drugs require, so its absorption and effect cannot be assumed to match brand-name Belsomra. Most insurance plans, including Pennsylvania Medicaid, generally do not cover compounded medications, though coverage exceptions vary and should be confirmed with the specific plan.

Telehealth prescribing in Pennsylvania

Pennsylvania law permits licensed prescribers to evaluate patients by real-time video and prescribe Schedule IV controlled substances, including suvorexant, when a legitimate prescriber-patient relationship has been established. The specific statutory framework and any requirements around electronic prescribing for controlled substances have been updated over time at both the state and federal level, so a prescriber's office or telehealth platform is the accurate source for current requirements rather than a fixed citation to a specific act or year. Regardless of the visit format, the same clinical evaluation standards apply: a documented history, a clinical rationale for choosing suvorexant over other options, and adherence to FDA labeling for dosing and contraindications.

The FDA-approved prescribing information for Belsomra recommends a starting dose of 10 mg taken within 30 minutes of bedtime, with at least 7 hours remaining before planned waking, and a maximum of 20 mg nightly. Suvorexant should not be combined with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or clarithromycin, and the dose is limited to 5 mg with moderate CYP3A4 inhibitors. This is general labeling information, not individualized dosing advice; your prescriber determines the appropriate starting dose based on your specific medications and health history. (FDA prescribing information)

How suvorexant compares with other insomnia drugs on cost and mechanism

Generic zolpidem and generic eszopiclone are typically the least expensive prescription options and are usually first-line on insurance formularies, in part because they are older, generic, and priced accordingly. They work through GABA-A receptor agonism rather than orexin blockade and carry a labeled risk of complex sleep behaviors and next-day sedation. Lemborexant (Dayvigo) is a second DORA, approved after suvorexant, and is generally priced similarly to Belsomra as a brand-name product without a generic. Trazodone is commonly prescribed off-label for insomnia at low generic cost, despite lacking an FDA indication for that use, and carries its own risks including orthostatic hypotension.

A randomized controlled trial supporting suvorexant's approval reported improvements in both subjective and objective measures of sleep onset and maintenance compared with placebo, with somnolence as the most common adverse effect. A separate randomized trial evaluated lemborexant against placebo and extended-release zolpidem in older adults with insomnia. Both of these trials, along with guideline statements from sleep medicine specialty organizations describing DORAs as having a favorable profile relative to benzodiazepine receptor agonists regarding rebound insomnia, are frequently cited in discussions of this drug class. This article is not attaching specific PubMed identifiers to these trials because the identifiers inherited from the prior draft could not be verified against the correct papers; anyone citing exact effect sizes, adverse event percentages, or number-needed-to-treat figures for suvorexant or lemborexant should pull the specific peer-reviewed source and confirm it before publishing that number.

Suvorexant safety basics relevant to cost decisions

Suvorexant's FDA label carries warnings regarding CNS-depressant effects, sleep paralysis, hypnagogic or hypnopompic hallucinations, and the potential for worsening depression or suicidal ideation; these are labeled risks that warrant monitoring rather than reasons to avoid the drug automatically. Unlike benzodiazepines and "Z-drug" sedative-hypnotics, suvorexant is not associated with the same pattern of tolerance and withdrawal, though it remains a Schedule IV controlled substance and should not be combined with alcohol due to additive CNS depression. If a patient develops worsening depression, suicidal thoughts, or unusual sleep-related behavior while taking suvorexant, that requires prompt contact with the prescriber or urgent care, not a wait-and-see approach.

Evidence boundary: what is established, what is plausible, what is not established

Established: suvorexant/Belsomra is FDA-approved for insomnia, dosed at 5 to 20 mg at bedtime, is a Schedule IV controlled substance, has no FDA-approved generic as of May 2026 per the Orange Book, and carries labeled warnings around CNS depression and psychiatric effects. Plausible but requiring current verification: specific cash prices, specific insurer copay tiers, specific Medicaid prior authorization turnaround times, and specific manufacturer savings card terms, all of which change year to year and were not independently confirmed for this draft. Not established from the material available here: a precise statewide average cash price for Pennsylvania, exact numeric comparative effect sizes (such as a specific number-needed-to-treat) for suvorexant versus lemborexant, and any named individual's quoted opinion, since no verifiable attributed quotation was available.

Verification checklist: stable facts versus facts that expire

Use this before acting on any cost or coverage claim about Belsomra in Pennsylvania, including the ones in this article.

Stable, unlikely to change without an FDA or federal action (safe to treat as durable):

• Suvorexant's FDA-approved indication, dosage strengths (5/10/15/20 mg), and Schedule IV status
• The FDA label's dosing framework (bedtime dosing, 7-hour rule, CYP3A4 interaction caution)
• The general legality of 503A compounding under federal law, subject to state pharmacy board oversight
• The absence of an FDA-approved generic, confirmed by checking the current Orange Book entry

Date-sensitive, must be re-verified before you rely on it (check within the last 30 to 60 days):

• Manufacturer list price and any manufacturer savings card dollar cap or eligibility rule
• Retail cash price at a specific Pennsylvania pharmacy
• Your specific insurer's formulary tier, prior authorization criteria, and copay amount
• Pennsylvania Medicaid MCO prior authorization criteria and processing time
• Medicare Part D formulary tier and copay for your specific plan
• Federal poverty level income threshold used for manufacturer patient assistance eligibility
• Third-party discount card (GoodRx, SingleCare, RxSaver) pricing at a named pharmacy

How to verify each date-sensitive item: call the pharmacy directly for cash price, call the number on your insurance card for formulary and copay details, check your Medicaid MCO's published prior authorization list or ask your prescriber's office to confirm, and check the manufacturer's current savings program page rather than relying on a screenshot or article from a prior year.

Practical steps to reduce your cost

1. Confirm your plan's formulary tier and prior authorization requirement for Belsomra before your prescriber sends the prescription.
2. Ask your prescriber's office to submit prior authorization proactively rather than waiting for a pharmacy denial.
3. If commercially insured, ask about the current Merck savings card terms; it does not apply to Medicare, Medicaid, or Tricare.
4. Compare your insured copay against a GoodRx, SingleCare, or RxSaver cash price at the same pharmacy, since the discount price sometimes beats the copay, particularly on high-deductible plans early in the year.
5. Ask about 90-day mail-order fills, which some Pennsylvania plans price lower per unit than 30-day retail fills.
6. If uninsured and low-income, ask your prescriber about applying to Merck's patient assistance program, and confirm the current income threshold directly with the program.